Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

doi:10.12998/wjcc.v9.i18.4491

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3522)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

276

WORD

HTML

2094

Figures (1-1)

191

Tables (1-2)

216

Sum=2868

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

217

Download

437

Sum=654

Jun 26, 2021 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jun 26, 2021; 9(18): 4491-4499
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4491

Table 1 Prevalence and sustained virologic response after hepatitis C virus treatment in patients with hepatitis C virus monoinfection compared to patients with hepatitis C virus/human immunodeficiency virus coinfection

	HCV monoinfection	HCV/HIV coinfection
Prevalence	184 million person worldwide	2.3 million person worldwide
SVR after interferon treatment	36%-76% (genotype 1, 2, 3, 4, treatment naïve)	18.4%-50% (genotype 1, 2, 3, 4, treatment naïve)
SVR after DAA treatment	96%-100% (pangenotype, treatment naïve)	95%-98% (pangenotype, treatment naïve)

DAA: Direct-acting antiviral; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; SVR: Sustained virologic response.

Citation: Laiwatthanapaisan R, Sirinawasatien A. Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults. World J Clin Cases 2021; 9(18): 4491-4499
URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4491.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4491